Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Multi-Billion Dollar Price Tag of U.S. Rare Earth Independence

    As geopolitical risks rise, the U.S. is pouring capital into building a domestic rare earth supply chain—an effort with massive costs, tight timelines, and significant investment implications.

    Read more

  • How Do I Sell My Business…or Complete a Dividend Recapitalization Process?

    We have outlined below a brief “business for sale” process, followed by dividend recapitalization information built by the expertise of professionals at William Blair.

    Read more

  • How to Develop the Right Personal Wealth Strategy Before a Business Liquidity Event

    Time is your most valuable resource—the earlier you start wealth planning, the more opportunities you have.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures